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Abstract
The objective of this study was to develop a novel peptide nucleic
acid (PNA) probe for Stenotrophomonas maltophilia identification by
fluorescence in situ hybridization (FISH). The probe was evaluated
using 33 human and veterinary clinical S. maltophilia isolates and 45
reference strains representing common bacterial species in the
respiratory tract. The probe displayed 100% sensitivity and 100%
specificity on pure cultures and allowed detection in sputum from
cystic fibrosis patients. The detection limit was 104 CFU/mL in
spiked tracheal aspirate and bronchoalveolar lavage from healthy
horses. Altogether the study shows that this species-specific PNA
FISH probe facilitates rapid detection of S. maltophilia in biological
specimens.
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Stenotrophomonas maltophilia is a Gram-negative bacterium
ubiquitous in nature [1]. It is capable of causing serious disease
in immuno-compromised patients and has been reported in
cystic fibrosis (CF) patients with a yearly prevalence of up to
25% [2, 3]. In veterinary medicine, an increasing number of
studies indicate possible associations with respiratory disease
[4, 5], bacterial cystitis and endocarditis [6], urinary tract
infections [7] and lymphadenitis [8]. Within the genus, S.
maltophilia is the only species that is known to colonize and
cause respiratory tract infections in humans and animals.
The objective of this study was to design and evaluate a
novel peptide nucleic acid (PNA) probe for S. maltophilia
identification by fluorescence in situ hybridization (FISH). A
PNA probe targeting 16S rRNA (Flu-OO-CGCCATG-
GATGTTCC, 5′-3′) specific for S. maltophilia and conjugated
with fluorescein isothiocyanate (FITC) was added a PNA
blocker probe (Ac-CCACGGATGTTCC, 5′-3′) to prevent
cross-reaction with closely related species such as Xanthomo-
nas campestris (Panagene, Daejeon, Korea). Sensitivity and
specificity of the probe were evaluated using 35 human and
veterinary clinical S. maltophilia isolates, and 43 reference and
clinical strains representing common bacterial species in the
airways of humans and animals (Table 1). All strains were
cultured on solid media (5% calf blood agar, chocolate agar or
nutrient/yeast/glycerol agar as deemed appropriate) and
sub-cultured in tryptic soy broth. Ten microlitres of broth
were placed onto a microscopic slide prepared with one drop
of fixation solution (phosphate-buffered saline with detergent)
and fixed by heating (methanol fixation for sputum smears).
After adding one drop of hybridization solution (AdvanDx,
Woburn, MA, USA) containing the S. maltophilia PNA probe, a
coverslip was applied and hybridization performed by incubat-
ing the slides at 55°C for 30 min (90 min for sputum smears).
Limited to Gram-negative strains, slides were immersed in
preheated deionized water (55°C) for 1 min. All slides were
then placed in a wash jar with a preheated (55°C) wash
solution (diluted Tris-buffered saline with detergent) in a water
bath for 30 min, coverslips removed. After air drying, a drop of
mounting medium (photobleaching inhibitor in glycerol) and a
coverslip were applied. A positive control slide with S.
maltophilia and a negative control slide with the relevant strain
hybridized with a universal PNA FISH probe (BacUni PNA,
AdvanDx) according to manufacturer’s instructions were
included in all runs. All slides were evaluated within 2 h under
a fluorescence microscope (960 objective, Olympus BX51,
Ballerup, Denmark; Mercury U-LH100HG 100 W lamp)
equipped with an FITC/Texas Red Dual Band Filter. Fluores-
cence images were obtained using an Olympus DP72 camera
(1360 9 1024 pixels, 1 s exposure). Samples were considered
positive when single cells had a strong fluorescence and clear
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morphology (Fig. 1). The probe yielded positive results with all
target organisms and negative results with all non-target
organisms (100% sensitivity and 100% specificity).
The probe was tested on spiked respiratory samples of
equine origin to determine the detection limit. Tracheal
aspirate (TA) and bronchoalveolar lavage (BAL) samples from
three healthy horses were spiked with S. maltophilia ATCC
13637. Ten-fold dilution series were prepared from the spiked
TA/BAL samples and PNA FISH smears were prepared for
each dilution as described above but without fixation solution.
The detection limit was determined by parallel plating of the
dilutions on blood agar for colony counts. Fluorescence
microscopy of the smears showed at least one to ten S.
maltophilia cells in most fields when the concentration in the
sample was 104 CFU/mL. The probe specificity was further
tested on sputum samples from seven patients with CF. The
samples underwent routine culture at the University Hospital
of Copenhagen, Denmark. The probe produced positive
results in all four samples from S. maltophilia-infected patients
and negative results in all control samples (two patients
infected with Pseudomonas aeruginosa, one patient infected with
Burkholderia multivorans). No background fluorescence was
observed.
Isolation and identification of S. maltophilia can be problem-
atic [9–13]. Selective differential media have been recom-
mended for improved detection of S. maltophilia from
non-sterile sites such as respiratory secretions [14–16].
Problems related to misidentification of S. maltophilia by
phenotypic methods can be overcome by the use of molecular
methods. Pinot et al. [17] used vancomycin, imipenem,
amphotericin B medium agar for isolation and multiplex PCR
for identification of S. maltophilia. Hogardt et al. [18] designed a
species-specific DNA probe for S. maltophilia identification and
demonstrated that the probe could be used successfully on
sputum and throat samples from CF patients. However, the
limit for microscopic detection of bacteria within sputum was
4 9 105 CFU/mL and the sensitivity of the DNA FISH method
(90%) was lower than that of the PNA FISH approach
described in this study. PNA probes are small in size with a
non-charged polyamide backbone that renders them easy to
hybridize and increases the binding strength compared to
DNA probes [19]. PNA probes have better sensitivity and
specificity, show improved penetration into cells and through
biofilm matrices and are not susceptible to bacterial endonuc-
leases which may be present in clinical samples [20]. PNA FISH
is a very fast (less than 90 min) and reliable molecular
identification method which is easy to perform with very little
hands-on time. Furthermore, FISH is useful for in situ detection
of this microorganism directly in clinical samples and mixed
bacterial populations without prior cultivation. Thus, the S.
maltophilia PNA FISH probe described in this study has
TABLE 1. Reference and clinical strains used for probe evaluation.
Proteus mirabilis ATCC 12453 Streptococcus dysgal. subsp. dysgalactiaeT CCUG 27301
Bacillus cereusa S31A8a Streptococcus dysgal. subsp. equisimilis ATCC 12388
Escherichia coli ATCC 35218 Streptococcus equi subsp. zooepidemicus CCUG 23256
Enterococcus faecalisT ATCC 19433 Streptococcus equi subsp. equi ATCC 9528
Enterobacter aerogenesT ATCC 13048 Streptococcus suisT CCUG 7984
Serratia marcescens ATCC 14756 Streptococcus bovisT CCUG 17828
Citrobacter freundii ATCC 43864 Streptococcus pneumoniae ATCC 10015
Staphylococcus epidermidis ATCC 12228 Actinobacillus equuli subsp. equulia S55G3a
Staphylococcus aureusT ATCC 12600 Alcaligenes spp.a S61E5a
Hafnia alveia S24B4a Corynebacterium diphtheriae ATCC 27010
Pasteurella multocida ATCC 12945 Bordetella bronchisepticaa S31B7a
Neisseria meningitidis ATCC 13102 Klebsiella pneumoniae subsp. pneumoniaeT ATCC 13883
Acinetobacter baumanniiT ATCC 19606 Klebsiella pneumoniae subsp. pneumoniae ATCC 10031
Moraxella bovisa S31B1a Xanthomonas campestris pv. campestris Strain 8004
Moraxella catarrhalis ATCC 25240 Pseudomonas fluorescensT ATCC 13525
Moraxella nonliquefaciensT ATCC 19975 Pseudomonas alcaligenesT ATCC 14909
Haemophilus influenzae ATCC 19418 Pseudomonas putida ATCC 49128
Burkholderia cepacia ATCC 25416 Pseudomonas stutzeriT ATCC 17588
Burkholderia multivorans CF 54b Pseudomonas aeruginosaT ATCC 10145
Stenotrophomonas acidaminiphilaT ATCC 700916 Pseudomonas aeruginosa PAO1b, CF15b, CF16b
Stenotrophomonas maltophiliaT ATCC 13637
Stenotrophomonas maltophilia Veterinary clinical strains n = 22a and human clinical strains n = 13b
aFrom the Department of Veterinary Disease Biology, University of Copenhagen, Denmark.
bFrom the Department for Clinical Microbiology, University Hospital of Copenhagen, Denmark.
FIG. 1. PNA FISH (peptide nucleic acid fluorescence in situ hybrid-
ization) microscopy of Stenotrophomonas maltophilia.
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important applications for studies of biofilm infections and S.
maltophilia colonization in patients with CF, where colonization
and chronic infection with S. maltophilia is commonly reported.
In conclusion, the S. maltophilia PNA FISH probe demon-
strated excellent sensitivity and specificity when tested against
clinically relevant bacteria occurring in the respiratory tract of
humans and animals. The PNA FISH assay can be implemented
in diagnostic laboratories for rapid, simple and reliable in situ
identification of S. maltophilia in clinical specimens. It can only
be a valuable tool for research aimed at understanding the role
played by this organism in CF and in equine respiratory tract
infections. For this purpose, further studies are warranted to
evaluate the use of the probe for studying spatial distribution
of S. maltophilia in polymicrobial biofilms.
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